• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » General Electric jumps on Street-beating Q3 results, raised earnings outlook

General Electric jumps on Street-beating Q3 results, raised earnings outlook

October 30, 2019 By Brad Perriello

General ElectricGeneral Electric (NYSE:GE) shares got a bump in pre-market trading today after the industrial conglomerate posted third-quarter results that beat the consensus forecast and raised its earnings outlook for the rest of the year.

Boston-based GE reported losses of -$9.47 billion, or -$1.08 per share, on sales of $23.36 billion for the three months ended Sept. 30, paring its losses by -58.5% on flat sales compared with Q3 2018.

Adjusted to exclude one-time items, earnings per share were 15¢, 4¢ ahead of the consensus on Wall Street, where analysts were looking for revenues of $22.93 billion.

“Our results reflect another quarter of progress in the transformation of GE. We are encouraged by our strong backlog, organic growth, margin expansion and positive cash trajectory amidst global macro uncertainty. We are raising our industrial free cash flow outlook again, even with external headwinds from the 737 MAX and tariffs, and we are holding our adjusted EPS outlook despite reduced income from moving Baker Hughes to discontinued operations,” chairman & CEO Lawrence Culp Jr. said in prepared remarks. “This quarter, during strategy reviews with each of our businesses, we identified and prioritized operating improvements and growth investments that will drive sustainable results. We have more work to do, and we will continue to take actions to improve our financial position and strengthen our businesses as we prepare for 2020 and beyond. I remain confident that we will unlock value for GE’s stakeholders as our transformation accelerates.”

GE said it now expects to report adjusted EPS of 55¢ to 65¢ this year, up from 50¢ to 55¢ previously.

The results sent GE shares, which closed flat at $9.07 apiece yesterday, up some 8.2% to $9.78 each today before the market’s open.

Healthcare profits gain on mid-single-digit top-line growth

GE Healthcare reported profit growth of 13.1% to $974 million on sales growth of 4.6% to $4.92 billion, compared with Q3 2018, the company said.

GE attributed the growth of healthcare business profits to “volume and cost productivity, partially offset by inflation, tariffs and program investments.”

Filed Under: Featured, MassDevice Earnings Roundup, Wall Street Beat

More recent news

  • Sequel Med Tech’s automated twiist pump scores FDA clearance in type 2 diabetes
  • FDA posts alert for Edwards Lifesciences mitral valve delivery system after patient death
  • Former Medtronic RDN leader joins Teleflex
  • CMR Surgical CEO outlines the path forward for Stryker’s robotics partnership
  • Stryker earns FDA clearance for new bone and soft tissue removal platform

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy